In his complaint, Michael Wade Nance said his veins were so severely compromised that they were likely to blow and cause him ...

A new RNA-based therapy developed at Columbia University could help the heart repair itself after a heart attack without invasive surgery.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

For many Americans struggling to lose weight, powerful new medications are changing the game. With roughly 40% of U.S. adults living with obesity, according to the Centers for Disease Control ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Pooled HELIOS-A/HELIOS-B safety included 707 patients (30.3% hereditary; remainder wild-type) with median 33.4 months of therapy and exposure up to 58 months. Exposure-adjusted overall and serious ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...

The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

This once-weekly C-type natriuretic peptide analog functions by antagonizing overactive FGFR3 signaling to improve growth in pediatric patients.